Revance Therapeutics (RVNC) News Today $3.80 +0.04 (+1.06%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Revance Therapeutics gains as Crown Labs further extends tender offerNovember 21 at 3:44 AM | msn.comAlpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Alpine Associates Management Inc. acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,162,861 shares of the biopharmaceutical companyNovember 20 at 6:57 AM | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.comNovember 20 at 2:27 AM | americanbankingnews.comBarclays Remains a Hold on Revance Therapeutics (RVNC)November 19 at 6:48 AM | markets.businessinsider.comLMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC)LMR Partners LLP acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,244,400 shares of the biopharmaceutical compNovember 18 at 7:38 AM | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Monday. They set a "hold" rating for the company.November 18 at 3:15 AM | marketbeat.comBrokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $9.66November 17, 2024 | americanbankingnews.comRevance Therapeutics jumps after Crown Laboratories tender offer extended againNovember 13, 2024 | msn.comCautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties with Crown LaboratoriesNovember 13, 2024 | markets.businessinsider.comRevance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.comNovember 13, 2024 | americanbankingnews.comStifel Nicolaus Remains a Hold on Revance Therapeutics (RVNC)November 12, 2024 | markets.businessinsider.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from AnalystsRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given an average rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. TheNovember 12, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 10, 2024 | prnewswire.comStockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)StockNews.com began coverage on shares of Revance Therapeutics in a research report on Sunday. They set a "hold" rating on the stock.November 10, 2024 | marketbeat.comRevance Therapeutics Reports Q3 Growth Amid Merger PlansNovember 9, 2024 | markets.businessinsider.comRevance withdraws previously provided guidanceNovember 8, 2024 | markets.businessinsider.comRevance Therapeutics sinks amid `going concern' disclosureNovember 8, 2024 | seekingalpha.comRevance Therapeutics' (RVNC) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $6.60 price target on shares of Revance Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNovember 7, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 2, 2024 | prnewswire.comLost Money on Revance Therapeutics, Inc. (RVNC)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyNovember 1, 2024 | stockhouse.comRevance Therapeutics (NASDAQ:RVNC) Stock, Insider Trading ActivityOctober 29, 2024 | benzinga.comRevance Therapeutics surges after Crown tender offer extended, settles with TeoxaneOctober 29, 2024 | msn.comRevance Therapeutics Sees Unusually High Options Volume (NASDAQ:RVNC)Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) was the recipient of unusually large options trading on Monday. Traders purchased 2,392 put options on the stock. This is an increase of approximately 144% compared to the typical daily volume of 981 put options.October 28, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Shares Gap Up - Still a Buy?Revance Therapeutics (NASDAQ:RVNC) Shares Gap Up - Should You Buy?October 28, 2024 | marketbeat.comRevance Shares Rise Premarket on Teoxane Settlement, Tender ExtensionOctober 28, 2024 | marketwatch.comRevance Therapeutics drops as deadline for Crown Lab tender set to expireOctober 25, 2024 | msn.comRevance Therapeutics (NASDAQ:RVNC) Shares Down 3.8% - Here's What HappenedRevance Therapeutics (NASDAQ:RVNC) Stock Price Down 3.8% - Here's WhyOctober 25, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 25, 2024 | prnewswire.comRevance Therapeutics, Crown Labs Again Extend Tender Offer DeadlineOctober 18, 2024 | marketwatch.comRevance Therapeutics (RVNC) Gets a Hold from Mizuho SecuritiesOctober 18, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 17, 2024 | prnewswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of InvestorsOctober 15, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of InvestorsOctober 15, 2024 | businesswire.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Up 25.0% in SeptemberRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 9,540,000 shares, a growth of 25.0% from the September 15th total of 7,630,000 shares. Based on an average trading volume of 4,740,000 shares, the days-to-cover ratio is presently 2.0 days.October 15, 2024 | marketbeat.comAQR Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)AQR Capital Management LLC grew its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 567.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,080 shares of the biopharmaceuOctober 15, 2024 | marketbeat.comAlgert Global LLC Lowers Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Algert Global LLC trimmed its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 92.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,000 shares of the biopharmaceutical company's stock after selling 127,260 shares durinOctober 13, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 9, 2024 | prnewswire.comRenaissance Technologies LLC Has $1.47 Million Stake in Revance Therapeutics, Inc. (NASDAQ:RVNC)Renaissance Technologies LLC increased its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 53.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 572,000 shares of the biopharmaceuticaOctober 5, 2024 | marketbeat.comRevance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Oct. 18 >RVNCOctober 4, 2024 | marketwatch.comRevance Therapeutics, Crown Labs tender offer extended until Oct. 18October 4, 2024 | msn.comRevance Therapeutics merger delayed due to alleged contract breechOctober 4, 2024 | bizjournals.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCOctober 3, 2024 | prnewswire.comRevance Therapeutics, Inc. (NASDAQ:RVNC) is Stonepine Capital Management LLC's 5th Largest PositionStonepine Capital Management LLC lifted its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 41.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,800,000 shares of the biopharmaceOctober 1, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCSeptember 25, 2024 | prnewswire.comRevance Therapeutics Shares Fall on Crown Labs Deal DelaySeptember 23, 2024 | marketwatch.comRevance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane disputeSeptember 23, 2024 | seekingalpha.comIntegral Health Asset Management LLC Makes New $1.29 Million Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC)Integral Health Asset Management LLC purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 500,000 shares of the biophaSeptember 23, 2024 | marketbeat.com Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! RVNC Media Mentions By Week RVNC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼0.370.46▲Average Medical News Sentiment RVNC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼63▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARCT News Today MRSN News Today HRTX News Today STOK News Today GBIO News Today STTK News Today KNSA News Today ARVN News Today INDV News Today SYRE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
